Scientists hunt for clues in blood and tumors to predict Cancer's next move
NCT ID NCT07507578
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This observational study aims to understand why metastatic adenoid cystic carcinoma (ACC) of the head and neck behaves differently in different people. Researchers will analyze stored tumor tissue and blood samples from 114 adults to see if certain biological types (ACC-I or ACC-II) are linked to how fast the cancer grows. No experimental treatment is given; participants continue their usual care while providing samples every 6 months for up to 2 years.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could reveal biological markers that help doctors predict how aggressive a patient's cancer will be and guide future personalized treatments.
- What could go wrong
- This is an observational study, not a treatment trial. It will not directly benefit participants, and the findings may not lead to new therapies for many years, if at all.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 114 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2025
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Metastatic adenoid cystic carcinoma of head and neck
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Pathologic diagnosis of ACC * Primary ACC arising from the head and neck * Unequivocal clinical and/or radiological evidence of metastatic disease * Patient ability and availability to comply with study protocol procedures. Exclusion Criteria: * ACC patients with local and/or regional recurrence without distant metastases * Primary ACC arising from any non-head and neck region (e.g., breast, lung, skin etc) * Insufficient data about previous medical history.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Adenoid cystic carcinoma of the head and neck are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Fondazione IRCCS Istituto Nazionale dei Tumori
RECRUITINGMilan, 20133, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill target multiple Hard-to-Treat cancers?
- New targeted pill holds promise for rare salivary gland cancer that spreads
- New combo therapy takes aim at Hard-to-Treat salivary gland cancer
- GPS for surgeons: new navigation tool aims to improve head and neck cancer outcomes
- Microchip implant could personalize cancer drug selection